Drug Profile
Research programme: protein kinase inhibitors - SignalChem Lifesciences
Alternative Names: SLC-0121; SLC-0131Latest Information Update: 14 Feb 2019
Price :
$50
*
At a glance
- Originator SignalChem Lifesciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Carbonic anhydrase inhibitors; Interleukin-1 receptor-associated kinase inhibitors; LRRK2 protein inhibitors; NF kappa B kinase inhibitors; Tau tubulin kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Autoimmune disorders; Cancer; Inflammation; Parkinson's disease
Most Recent Events
- 13 Feb 2019 Discontinued - Preclinical for Cancer in Canada (unspecified route) (SignalChem Lifesciences pipeline, February 2019)
- 12 Feb 2019 Discontinued for Alzheimer's disease in Canada (unspecified route) (SignalChem Lifesciences pipeline, February 2019)
- 12 Feb 2019 Discontinued for Autoimmune disorders in Canada (unspecified route) (SignalChem Lifesciences pipeline, February 2019)